Horizon Discovery and AstraZeneca have entered into a research collaboration and license agreement to explore oncology-relevant genotypes with the goal of identifying and validating novel drug targets. This is the second collaboration between the companies, including an oncology discovery program to explore Horizon’s kinase target program, HD-001.   Horizon will explore a defined set of genotypes for synthetic lethality, and will provide in vitro screening using its siRNA platform. Any resulting...